Sarcopenia and Neuroendocrine Neoplasms

Curr Oncol Rep. 2024 Feb;26(2):121-128. doi: 10.1007/s11912-024-01494-w. Epub 2024 Jan 25.

Abstract

Purpose of the review: To summarise the current literature regarding the presence of sarcopenia in patients with neuroendocrine neoplasms (NENs). These are uncommon cancers separated into well-differentiated neuroendocrine tumours (NETs) and poorly differentiated neuroendocrine carcinoma (NECs). For the diagnosis of sarcopenia, there needs to be low muscle strength and low muscle quantity/quality.

Recent findings: Five studies exist describing either low muscle strength or low muscle quantity in patients with NETs. The studies used different techniques to analyse muscle strength and muscle quantity, included heterogeneous populations, and performed the analysis at different time points following the diagnosis of the NET. Only 2 studies regarding patients with NECs could be found, both included mainly patients with a mixed adenoneuroendocrine carcinoma (MiNEN) and are, therefore, difficult to interpret for patients with a NEC. The main findings of this review are to describe the presence of sarcopenia in patients with NENs. However, results should be interpreted with caution, and future research should focus on the correct technique, homogenous population and same time point.

Keywords: Malnutrition; Neuroendocrine carcinoma; Neuroendocrine neoplasms; Neuroendocrine tumours; Sarcopenia; Survival.

Publication types

  • Review

MeSH terms

  • Carcinoma, Neuroendocrine* / pathology
  • Gastrointestinal Neoplasms*
  • Humans
  • Neuroendocrine Tumors* / pathology
  • Pancreatic Neoplasms* / pathology
  • Sarcopenia* / complications
  • Stomach Neoplasms* / pathology